Jazz sells sleep and cancer medicines including Xywav.
Jazz Pharmaceuticals plc (JAZZ) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:07 ET. Consensus EPS estimate is $6.30.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-03 | Jun 2026 qtr | $6.18 | $5.71 | -7.6% | $1.21B |
| 2026-05-05 | Mar 2026 qtr | $4.64 | $6.34 | — | $1.07B |
| 2026-02-24 | Dec 2025 qtr | $6.52 | $6.64 | +1.8% | $1.20B |
| 2025-11-05 | Sep 2025 qtr | $5.95 | $8.13 | — | $1.13B |
| 2025-08-05 | Jun 2025 qtr | $-6.12 | $-8.25 | — | $1.05B |
| 2025-05-06 | Mar 2025 qtr | $4.51 | $1.68 | — | $897.84M |
| 2025-02-25 | Dec 2024 qtr | $5.83 | $6.60 | +13.2% | $1.09B |
| 2024-11-06 | Sep 2024 qtr | $5.47 | $6.61 | — | $1.05B |
JAZZ has beaten consensus EPS in 2 of its last 3 scored quarters.
See JAZZ on the live calendar →